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Background: There is little or no information available on the impact of funding by the food industry on trial
outcomes and methodological quality of synbiotics, probiotics and prebiotics research in infants. The objective of
this study was to compare the methodological quality, outcomes of food industry sponsored trials versus non
industry sponsored trials, with regards to supplementation of synbiotics, probiotics and prebiotics in infant formula.
Methods: A comprehensive search was conducted to identify published and unpublished randomized clinical trials
(RCTs). Cochrane methodology was used to assess the risk of bias of included RCTs in the following domains: 1)
sequence generation; 2) allocation concealment; 3) blinding; 4) incomplete outcome data; 5) selective outcome
reporting; and 6) other bias. Clinical outcomes and authors’ conclusions were reported in frequencies and
percentages. The association between source of funding, risk of bias, clinical outcomes and conclusions were
assessed using Pearson’s Chi-square test and the Fisher’s exact test. A p-value < 0.05 was statistically significant.
Results: Sixty seven completed and 3 on-going RCTs were included. Forty (59.7%) were funded by food industry,
11 (16.4%) by non-industry entities and 16 (23.9%) did not specify source of funding. Several risk of bias domains,
especially sequence generation, allocation concealment and blinding, were not adequately reported. There was no
significant association between the source of funding and sequence generation, allocation concealment, blinding
and selective reporting, majority of reported clinical outcomes or authors’ conclusions. On the other hand, source
of funding was significantly associated with the domains of incomplete outcome data, free of other bias domains
as well as reported antibiotic use and conclusions on weight gain.
Conclusion: In RCTs on infants fed infant formula containing probiotics, prebiotics or synbiotics, the source of
funding did not influence the majority of outcomes in favour of the sponsors’ products. More non-industry funded
research is needed to further assess the impact of funding on methodological quality, reported clinical outcomes
and authors’ conclusions.
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There are numerous studies that explore the relationship
between industrial sponsorship of biomedical research
and published outcomes [1]. Several reviews have docu-
mented how trials funded by industry are more likely to
report results in favour of the sponsor’s products [2-5].
These reviews focused on trials sponsored by the
pharmaceutical industry. Few reviews have explored the
impact of funding by the food industry on outcomes of
research trials [6,7]. A review by Nkansah et al. also
found that majority of trials investigating the effects of
calcium supplementation in healthy children were indus-
try funded and all supported calcium supplementation,
in favour of the sponsor [8]. Similarly, a review by Lesser
et al. found that scientific nutrition related articles
(intervention trials, observational studies and scientific
reviews) on common consumed beverages (soft drinks,
juice, milk) funded by the food industry, were more
likely to be favourable to the sponsor than articles that
did not have industry funding [6].
Reporting only positive outcomes in a research trial
significantly reduces a sponsors’ financial risk. Pressure
to show a food product causes favourable outcomes in a
specific population, may result in biases in trial design
(methodology) and reporting of outcomes in industry
sponsored research. This type of bias in nutrition re-
search could adversely affect public health. Results from
nutrition research also influence policy formulation, pro-
fessional dietary guidelines, design of public health inter-
ventions and regulation of food product health claims.
In addition, findings from nutrition research often re-
ceive publicity from the media, which influences con-
sumer behaviour [6].
More studies are needed to explore the relationship be-
tween the food industry and nutrition research [7]. There
is little or no information available on the impact of fund-
ing by the food industry on trial outcomes and methodo-
logical quality of synbiotics, probiotics and prebiotics
research in infants. There are no systematic reviews that
have explored if sources of funding affects outcomes and
methodological quality of randomized controlled trials
(RCTs) conducted on infants given probiotics, prebiotics
or synbiotics supplemented infant formula.
Probiotics are defined as “live microorganisms” which
when administered in adequate amounts may confer a
health benefit to the host [9]. The main probiotic organ-
isms that are currently used worldwide belong to the gen-
era Lactobacillus and Bifidobacteria and are found in the
gastrointestinal microflora [9]. The probiotics preparations
of interest for this review are those added to infant formu-
las. Prebiotics are non- digestible food ingredients that
may benefit the host by selectively stimulating the growth
and/or activity of one or a limited number of bacteria in
the colon and improving the host’s health [10-12]. Themost widely studied prebiotics are galactooligosaccharides
(GOS), inulin and fructooligosaccharide (FOS) [13,14].
GOS, FOS and inulin are added to different foods as fat
and sugar replacements to improve texture or for their
functional benefits [10,15,16]. When probiotics and prebi-
otics are administered simultaneously, the combination is
termed Synbiotics.
The aim of this review was to explore whether finan-
cial sponsorship by the food industry affects outcomes
and methodological quality of trials on synbiotics, pro-
biotics or prebiotics used in infants. Methodological
quality may be compromised when insufficient informa-
tion is provided regarding sequence generation, alloca-
tion concealment, blinding, bias introduced from other
sources and incomplete outcome reporting.
Objective
The objective of this systematic review was to compare
the methodological quality and outcomes of food indus-
try sponsored trials versus non industry sponsored trials
with regards to supplementation of synbiotics, probiotics
and prebiotics in infant formula.
Hypothesis
The source of funding in research trials using probiotics,
prebiotics or synbiotics supplemented formula in infants
is associated with outcomes in favour of the sponsor’s
products and authors’ conclusions.
Methods
Criteria for considering studies for this review
Types of studies
All randomized controlled trials (RCTs) conducted from
1980 to 2012 (irrespective of language) on synbiotics, pro-
biotics, or prebiotics added to infant formula were in-
cluded. Study participants were healthy full term infants
(>37 weeks gestation or > 2.5 kg birth weight, 0–12 months
old), preterm infants (born < 37 weeks gestation), low birth
weight (<2.5 kg at birth) and extreme low birth weight in-
fants (<1000 g at birth). Infants were fed either infant for-
mula (preterm or full term formula), mixed feeds (breast
milk with infant formula) with added synbiotics, probiotics
or prebiotics or conventional infant formula with or with-
out placebo. RCTs were excluded if they included infants
with cardiac defects, pulmonary diseases, gastrointestinal
diseases, major congenital abnormalities or chromosomal
abnormalities. Commentaries, editorials, letters to the
editor and studies that were not RCTs were excluded.
Types of outcome
The outcomes included: 1) Source of funding, 2) Methodo-
logical quality (Risk of bias), 3) Clinical outcomes in RCTs,
4) Conclusions (Overall study conclusions and conclusions
on reported clinical outcomes) and 5) Association between
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comes and author’s conclusions.
Search methods for identification of studies
A literature search regardless of language was conducted on
electronic databases including The Cochrane CENTRAL
Register for Controlled Trials (2012), EMBASE (1980+),
Scopus (1980 to 2012), EBSCO host (1960 to 2012),
PUBMED / MEDLINE (1966 to 2012), OVID (1950 to
2012), SPORTDiscus (1960 to 2012), Web of Science (1970
to 2012), Science Direct (1950 to 2012), CINAHL (1980 to
2012), Science citation index (1970 to 2012), Latin American
Caribbean Health Sciences literature (LILACS) (1965 to
2012), NLMGateway (1950–1966). RCTs published in non-
English language journals were translated by independent
translators who were familiar with the subject matter.
The search strategy used to search PUBMED for
studies on full term infants is: (synbiotic* and probiotic*
OR prebiotic*) AND (FOS or fructooligosaccharide or
inulin or GOS or galactooligosaccharide) AND (infant
formula* OR infant feeding OR formula OR formula
milk) AND (infant* or baby or babies) NOT (preterm or
premature or low birth weight babies or allergy or ec-
zema) AND (randomized controlled trial* OR controlled
clinical trial* OR random allocation*) Limits: Humans.
This search strategy was modified to search other elec-
tronic databases and for studies on preterm infants.
A hand search was conducted on abstracts of major
conference proceedings such as the Pediatric Academic
Society meetings from 1990 (www.pas-meetings.org),
cross checked references cited in RCTs and in recent re-
views (published from 2003 to 2012) for additional RCTs
not identified by electronic searches and speciality journals
which were not included in any database such as Pedia-
trika and Chinese Journal of Microecology. To identify
on-going and unpublished trials, experts in the field, man-
ufacturers of infant formula containing probiotics and pre-
biotics were contacted. Web sites of companies that have
conducted or were conducting RCTs on probiotics and
prebiotics were searched.
Examples: Pfizer (www.pfizerpro.com/clinicaltrials),
Chris Hansen Laboratory (www.chr-hansen.com/research_
development/documentation.html). A search was con-
ducted on prospective trial registries such as World
Health Organization (WHO) International Clinical Trials
Registry Platform Search Portal (www.who.int/trialsearch),
Clinical Trials.gov register (www.clinicaltrials.gov),
Current Controlled Trials metaRegister of Control-
led Trials [mRCT] (www.controlled-trials.com/mrct)
and www.clinicaltrialresults.org.
Selection of studies
One reviewer (MM) independently reviewed all abstracts,
citations and identified potentially eligible RCTs. The fullreports of eligible RCTs were retrieved by one reviewer
(MM) and the pre-specified selection criteria applied in-
dependently by two reviewers (MM, ML) using a study
eligibility form designed for this review. If more than one
publication of a study existed, all reports of the study
were grouped together under one name. Any disagree-
ments between the reviewers were resolved through dis-
cussion. Unresolved disagreements were resolved by a
third party (RB).
Data extraction and management
Two reviewers (MM, ML) independently extracted data
using a pretested data extraction form that was designed
for this review. The reviewers (MM, ML) cross checked
data and resolved any differences through discussion.
Unresolved disagreements were resolved by a third party
(RB). One reviewer (MM) entered the data in SPSS ver-
sion 19 and the other reviewer (AM) conducted quality
control checks. The data obtained from each RCT
included:
A) Source of funding or support of RCTs
The source of funding or support of the RCTs was
defined and categorized as:
1) Industry included:
 For – profit company, donation of study product
by a for – profit company which manufactured
the study product,
 Not – for profit company that promoted the
consumption of synbiotics, probiotics or
prebiotics,
 Mixed sources (for-profit company and other
source).
2) Non – industry included:
 Government: National, regional (provincial,
county) government body with NO industry
association.
 Foundation / Philanthropies: examples include
Rockefeller foundation, Bill and Melinda Gates
foundation.
 Institution: University, Research centres, teaching
and academic hospitals.
 Other source of funding.
3) None: No source of funding was disclosed in study
report.
B) Assessment of methodological quality of evidence
(Risk of bias)
Two reviewers (MM, ML) independently assessed the
risk of bias of included RCTs as described in the
Cochrane Handbook for Systematic Reviews for Inter-
ventions according to the following 6 components:
1) sequence generation; 2) allocation concealment; 3)
Table 1 Included studies and on-going studies
Included studies On-going studies
Author publication year Full term/Preterm
infant
Sponsor Author publication year Full term/Preterm
infant
Sponsor Author, Year
study commenced
Full term/Preterm
infant
Allen 2010 [18] Full Term Knowledge exploitation
fund, collaborative
industrial research, others
Soh 2009 [19] Full Term National Medical
Research Council,
Singapore
Jacobs 2007 [20] Pre-Term
Alliet 2007 [21]
Scholtens 2008 [22]
Full Term Numico Urban 2008 [23] Full Term Nestle Patole 2009 [24] Pre-Term
Ashley 2012 [25] Full Term Mead Johnson Velaphi 2008 [26] Full Term Nestle Underwood 2009 [27] Pre-Term
Bakker-Zierikzee 2005 [28]
Bakker-Zierikzee 2006 [29]
Full Term None/Not clear Vendt 2006 [30] Full Term Valio Ltd
Bettler 2006 [31] Full Term Wyeth Nutrition Vlieger 2009 [32] Full Term Friesland
Brunser 2006 [33] Full Term None/Not clear Weizman 2005 [34] Full Term Materna Laboratories
Bruzzese 2009 [35] Full Term Numico Weizman 2006 [36] Full Term Marterna Laboratories
Chouraqui 2004 [37] Full Term Nestle Xiao-Ming 2004 [38] Full Term Friesland
Chouraqui 2008 [39] Full Term Nestle Xiao-Ming 2008 [40] Full Term None / Not clear
Copper 2010 [41] Full Term Nestle Ziegler 2007 [42] Full Term Mead Johnson
Costalos 2008 [43] Full Term Numico Bin-Nun 2005 [44] Pre-Term Mr and Mrs Stephen
Hammerman, Mirsky
Research fund
Decsi 2005 [45] Full Term Numil Ltd Boehm 2002 [46]
Boehm 2003 [47]
Knol 2005 [48]
Pre-Term Numico
Fanaro 2005 [49] Full Term None / Not clear Chrzanowska-Liszewska 2012 [50] Pre-Term None/Not clear
Fanaro 2008 [51] Full Term Humana GmbH Costalos 2003 [52] Pre-Term None/Not clear
Gibson 2009 [53] Full Term Nestle Dani 2002 [54] Pre-Term None/Not clear
Gil-Campos 2012 [55] Full Term Puleva Indrio 2008 [56] Pre-Term Bio Gaia
Hascoet 2011 [57] Full Term Nestle Indrio 2009 [58] Pre-Term Numico
Holscher 2012a [59] Full Term Nestle Kapiki 2007 [60] Pre-Term None/Not clear
Holscher 2012b [61] Full Term Nestle Kitajima 1992 [62] Pre-Term None/Not clear
Kim 2010 [63] Full Term Ministry of Health, Welfare
and family affairs. Republic
of Korea
Lin H-C 2008 [64] Pre-Term National Science
Council of Taiwan
Knol 2005 [65] Full Term Numico Mihatsch 2006 [66] Pre-Term Milupa GmbH
Magne 2008 [67] Full Term Numico Mihatsch 2010 [68] Pre-Term Nestle
Mah 2007 [69] Full Term National Medical Research
Council Singapore
Millar 1993 [70]
Stansbridge 1993 [71]
Pre-Term Wessex Regional Health
Authority and childrens
Research fund
Maldonado 2010 [72] Full Term Puleva Modi 2010 [73] Pre-Term Danone
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Table 1 Included studies and on-going studies (Continued)
Moro 2002 [74]
Moro 2003 [75]
Full Term None/Not clear Mohan 2006 [76] Pre-Term None/Not clear
Moro 2005 [77] Full Term None/Not clear Reuman1986 [78] Pre-Term None/Not clear
Moro 2006 [79]
Arslanoglu 2007 [80]
Arslanoglu 2008 [81]
Van Hoffen 2009 [82]
Schouten 2011 [83]
Full Term Numico Riskin 2009 [84] Pre-Term None/Not clear
Piemontese 2011 [85] Full Term Danone Rouge 2009 [86] Pre-Term French Ministry of Health
Puccio 2007 [87] Full Term Nestle Sari 2011 [88] Pre-Term None/Not clear
Rautava 2006 [89]
Rautava 2009 [90]
Full Term Microbes and Man Research
program, Academy of Finland,
others
Stratiki 2007 [91] Pre-Term Nestle
Rinne 2005 [92] Full Term Academy of Finland, Turku
University Central Hospital
Research Funds
Westerbeek 2010 [93]
Westerbeek 2011a [94]
Westerbeek 2011b [95]
Pre-Term Danone
Saavedra 2004 [96] Full Term Nestle Yong 2009 [97] Pre-Term None/Not clear
Scalabrin 2009 [98] Full Term Mead Johnson
Scalabrin 2012 [99] Full Term Mead Johnson
Schmelzle 2003 [100] Full Term Numico
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Figure 1 Process of study selection.
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Table 2 Table of 56 Excluded studies with reasons for exclusion
Use of Exclusive
breast milk or Other
milk feeds (buffalo,
goat milk)
Type of feed
not clear/specified
Probiotic administered
in water, saline or
other fluid that is
not infant formula
No use of probiotic,
prebiotic
Not RCT, (Cross
over, Follow up,
Observational study)
Different inclusion
criteria
Lack of suitable/
knowledgeable
translator
Data presentation
inappropriate
Out dated
(published
before 1980)
Agarwal 2003 [101] Al Hosni 2012 [102] FengJuan 2008 [103] Morisset 2011 [104] Huet 2006 [105] Agustina 2007 [106] Akiyama1994a [107]
(Japanese)
Grzéskowak 2012 [108] Andrews 1969 [109]
Baldeon 2008 [110] Campeotto 2011 [111] Kuitunen 2009 [112] Patole 2005 [113] Bongers 2007 [114] Correa 2005 [115] Akiyama1994b [116]
(Japanese)
Robinson 1952 [117]
Braga 2011 [118] Cukrowska 2002 [119] Kukkonen 2007 [120] Rochat 2007 [121] Chou I-C 2009 [122] Hol 2008 [123]
Chandra 2002 [124] *Karvonen 1999 [125] Kukkonen 2008 [126] Taipale 2011 [127] Euler 2005 [128] Isolauri 2000 [129]
Lin H-C 2005 [130] *Karvonen 2001 [131] Taylor 2009 [132] Hoyos 1999 [133] Nopchinda 2002 [134]
Manzoni 2006 [135] *Karvonen 2002 [136] Thibault 2004 [137] Kim 2007 [138] Rivero 2004 [139]
Rinne 2006 [140] Li 2004 [141] Lee 2007 [142] Urao 1999 [143]
Samanta 2009 [144] Panigrahi 2008 [145] Lidesteri 2003 [146] Van der Aa 2010 [147]
Rojas 2012 [148] Marini 2003 [149] Waliogora-Dupriet 2007 [150]
Taylor 2007 [151] Rigo 2001 [152] Wang 2007 [153]
Underwood 2009 [154] Savino 2003 [155]
Sepp 1993 [156]
Key: * Unpublished trials.
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Table 3 Source of funding and study participants
Study participants
Sponsor Full term infant Preterm Infant Total
n n n (%)
Industry 33 7 40 (59.7)
None / Not Clear 6 10 16 (23.9)
Non Industry 6 5 11 (16.4)
Total 45 22 67 (100.0)
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http://www.biomedcentral.com/1471-2288/13/137blinding; 4) incomplete outcome data; 5) selective out-
come reporting; and 6) other sources of bias [17]. Each
domain was assessed as having either a low risk of bias,
high risk of bias or unclear to permit judgment. Any
disagreements regarding risk of bias were resolved
through discussion between MM, ML and RB. The asso-
ciation between risk of bias (domains) and type of funding
(industry, non – industry, none declared) was explored.
C) Assessment of clinical outcomes
The primary and secondary outcomes from each study
report were evaluated and categorized as:
1. Positive: synbiotic, probiotic or prebiotic
supplementation had a statistically significant
effect, p < 0.05.Table 4 Methodological quality (Risk of bias)
N (%)
Quality of studies N = 67 Low risk High risk Unclear
Sequence generation 42 (62.7) 25 (37.3)
Allocation concealment 32 (47.8) 35 (52.2)
Blinding 31 (46.3) 36 (53.7)
Incomplete Outcome data 52 (77.6) 1 (1.5) 14 (20.9)
Selective reporting 57 (85.1) 7 (10.4) 3 (4.5)
Other bias 53 (79.1) 14 (20.9)Examples of positive outcomes included: adequate
growth (weight gain, length gain, head
circumference), tolerance (no feeding problems),
microflora (increase in colony forming units of
bifidobacteria, lactobacillus, decrease in pathogens),
decreased infections (decrease in frequency, incidence
of infections).
2) Negative: synbiotic, probiotic or prebiotic
supplementation had a statistically significant effect
in an adverse event / negative outcome such as
weight loss, diarrhoea, p < 0.05
3) Neutral: synbiotic, probiotic or prebiotic
supplementation did not have a statistically
significant effect, p > 0.05, no significant differences
between study groups. Clinical outcomes included:
growth parameters, gastrointestinal parameters
(tolerance to feed, stool characteristics, microflora);
immune response, infections and mortality.
D) Overall study conclusions and conclusions on reported
outcomes
The authors’ overall study conclusion and conclusions
on reported clinical outcomes were evaluated and cate-
gorized as:
1. Positive: The author’s conclusion preferred the
sponsor’s products over control/placebo.
Interpretation of data supported the sponsor’s
products over control.
2. Negative: The sponsors’ products were not preferred
over control / placebo. Interpretation of data did
NOT support the sponsors’ products.
3. Neutral: The author’s conclusion was neutral to the
sponsor’s products.
4. No clear conclusion was offered by author.
In this review, the “conclusions on reported outcomes”
referred to the authors’ conclusions on individual reportedRCTs outcomes. Examples include conclusions on weight
gain, length gain, vomiting, necrotizing enterocolitis, sepsis.
Statistical Analysis
All the outcomes in this review were dichotomous and
are described in frequencies and percentages. The asso-
ciation between source of funding (industry/non-
industry/ none) and methodological quality (low/un-
clear/high risk of bias), clinical outcomes and author’s
conclusions were assessed using both the Pearson’s Chi-
square test and the Fisher’s exact test. A p-value of less
than 0.05 was considered statistically significant. SPSS
version 19 statistical software was used. A statistician
(AM) was consulted throughout the review process.
Ethics
The Human Research Ethics Committee at Stellenbosch
University, South Africa reviewed the protocol for this
review, ruled that all data to be collected for this review
was from the public domain and was therefore exempt
from ethical approval.
Results
Results of the search and description of studies
Electronic search of available databases yielded 290 cita-
tions. After reading titles and abstracts, duplicate reports
were removed, 226 articles were screened and 100 articles
were excluded. A hand search yielded 6 more articles. Po-
tentially relevant full text reports were retrieved, reviewed
for eligibility and a further 56 RCTs were excluded. Studies
that had multiple publications were considered as one
trial. Sixty seven RCTs and three on-going RCTs were
Table 5 Reported outcomes and conclusions
N (%)
Variable N= No conclusion Positive Neutral Negative
Variable N (%) Overall study conclusion 67 4 (6) 49 (73.1) 7 (10.4) 7 (10.4)
Reported Outcomes N= Positive* Neutral* Negative* Conclusion on reported outcomes
Weight gain 56 4 (7.1) 52 (92.9) Weight gain 56 40 (71.4) 15 (26.8) 1 (1.8)
Length gain 40 3 (7.5) 37 (92.5) Length gain 40 26 (65) 14 (35)
Head circumference 31 4 (12.9) 27 (87.1) Head circumference 31 17 (54.8) 14 (45.2)
Colic 13 1 (7.7) 12 (92.3) Colic 13 11 (84.6) 2 (15.4)
Spitting up/Regurgitation 26 2 (7.7) 23 (88.5) 1 (3.8) Spitting up/Regurgitation 26 23 (88.5) 3 (11.5)
Vomiting 31 1.5 (3.2 30 (96.8) Vomiting 32 24 (75) 8 (25)
Crying/Fussiness 22 3 (13.6) 18 (81.8) 1 (4.5) Crying/Fussiness 20 12 (60) 8 (40)
Gastric Residuals, Abdominal distension 5 1 (20) 4 (80) Gastric Residuals, Abdominal distension 6 3 (50) 3 (50)
Volume of formula consumed 31 3 (9.7) 27 (87.1) 1 (3.2) Volume of formula consumed 30 26 (86.7) 3 (10) 1(3.3)
Time to full enteral feeds 9 2 (22.2) 7 (77.8) Time to full enteral feeds 8 5 (62.5) 2 (25) 1 (12.5)
Stool frequency 37 10 (27) 27 (73) Stool frequency 38 27 (71.1) 11 (28.9)
Stool consistency 37 18 (48.6) 19 (51.4) Stool consistency 39 23 (59) 16 (41.0)
Stool pH 13 11 (84.6) 2 (15.4) Stool pH 12 7 (58.3) 5 (41.7)
Short chain fatty acids 9 3 (33.3) 6 (66.7) Short chain fatty acids 9 5 (55.6) 4 (44.4)
Flatulence/Gas 16 16 (100) Flatulence/Gas 15 11 (73.3) 4 (26.7)
Diarrhoea, Diarrhoea episodes 19 3(15.8) 15 (78.9) 1(5.3) Diarrhoea, Diarrhoea episodes 18 12 (66.7) 5 (27.8) 1 (5.6)
Constipation 3 1 (33.3) 2 (66.7) Constipation 4 3 (75) 1 (25)
Microflora - Bifidobacteria 31 23 (74.2) 8 (25.8) Microflora - Bifidobacteria 30 10 (33.3) 17 (56.7) 2 (6.7) 1 (3.3)
Microflora - Lactobacillus 19 8 (42.1) 11 (57.9) Microflora - Lactobacillus 19 9 (47.4) 8 (42.1) 1 (5.3) 1 (5.3)
Microflora - Pathogens 25 5 (20) 19 (76) 1 (4) Microflora - Pathogens 25 12 (48) 11 (44) 2 (8)
Immune response CRP, IL6, Cytokines 0 Immune response CRP, IL6, Cytokines 1 1 (100)
Immunoglobulins (IgA,IgG, Ig-Flc, IgE) 10 6 (60) 4 (40) Immunoglobulins (IgA,IgG, Ig-Flc, IgE) 10 4 (40) 6 (60)
Allergy 3 1 (33.3) 2 (66.7) Allergy 3 2 (66.7) 1 (33.3)
Eczema, Dermatitis, Rash, Skin Alterations 7 2 (28.6) 4 (57.1) 1 (14.3) Eczema, Dermatitis, Rash, Skin Alterations 7 5 (71.4) 1 (14.3) 1 (14.3)
Infections - Acute Otitis Media 3 3 (100) Infections - Acute Otitis Media 3 1 (33.3 2 (66.7)
Respiratory Infections 9 3 (33.3) 6 (66.7) Respiratory Infections 8 5 (62.5) 3 (37.5)
Gastrointestinal infections 6 1 (16.7) 5 (83.3) Gastrointestinal infections 4 1 (25) 3 (75)
Total infections, other unspecified infections 8 1 (12.5) 7 (87.5) Total infections, other unspecified infections 10 6 (60) 2 (20) 2 (20)
Urinary tract infections 2 2 (100) Urinary tract infections 2 1 (50) 1 (50)
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Table 5 Reported outcomes and conclusions (Continued)
Necrotizing Enterocolitis 11 2 (18.2) 9 (81.8) Necrotizing Enterocolitis 12 7 (58.3) 3 (25) 2 (16.7)
Sepsis 10 10 (100) Sepsis 10 9 (90) 1 (10)
Fever, Febrile Episodes 4 2 (50) 2 (50) Fever, Febrile Episodes 2 2 (100)
Antibiotic use 19 4 (21.1) 15 (78.9) Antibiotic use 16 13 (81.3) 3 (18.8)
Hospitalization 12 12 (100) Hospitalization 10 10 (100)
Biochemical measures 9 9 (100) Biochemical measures 6 5 (83.3) 1 (16.7)
Adverse events 18 2 (11.1) 16 (88.9) Adverse events 17 13 (76.5) 4 (23.5)
Death / Mortality 7 1 (14.3 6 (85.7) Death/Mortality 8 7 (87.5) 1 (12.5)
Intestinal permeability 3 1 (33.3) 2 (66.7) Intestinal permeability 3 1 (33.3) 2 (66.7)
Duration of TPN 5 5 (100) Duration of TPN 5 4 (80) 1 (20)
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05.
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05.
*Negative: synbiotic, probiotic or prebiotic supplementation had a statistically significant increase in an adverse event / negative outcome, p < 0.05.
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Table 6 Association between Sponsor and methodological quality (risk of bias)
Methodological quality Source of funding Yes (Low risk) No (High risk) Unclear Chi-square
p value
Fisher’s exact
p valueN = 67 studies n (%)$$ n (%)$$ n (%)$$
Sequence generation Industry 26 (38.8) 14 (20.9) 0.435 0.465
None/Not clear 8 (11.9) 8 (11.9)
Non industry 8 (11.9) 3 (4.5)
Allocation concealment Industry 21 (31.3) 19 (28.4) 0.315 0.338
None/Not clear 5 (7.5) 11 (16.4)
Non Iindustry 6 (9.0) 5 (7.5)
Blinding Industry 18 (26.9) 22 (32.8) 0.395 0.457
None/Not clear 6 (9.0) 10 (14.9)
Non industry 7 (10.4) 4 (6.0)
Incomplete outcome data Industry 36 (53.7) 1 (1.5) 3 (4.5) 0.023* 0.005*
None/Not clear 9 (13.4) 7 (10.4)
Non industry 7 (10.4) 4 (6.0)
Selective reporting Industry 36 (53.7) 2 (3.0) 2 (3.0) 0.224 0.188
None/Not clear 11 (16.4) 4 (6.0) 1 (1.5)
Non industry 10 (14.9) 1 (1.5) 0
Free of other bias Industry 35 (52.2) 5 (7.5) 0.033* 0.038*
None/Not clear 9 (13.4) 7 (10.4)
Non industry 8 (13.4) 1 (1.5) 2 (3.0)
*Significant p < 0.05.
$$Overall percentage.
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http://www.biomedcentral.com/1471-2288/13/137included in this review. (Table 1) The selection process is
shown in Figure 1. Table 2 gives a list of 56 RCTs which
were excluded for: use of exclusive breast or non-formula
milk (8 RCTs), type of feed not clear (11 RCTs), probiotic
administered in saline, water or other fluid (4 RCTs), no
use of probiotic or prebiotic (6 RCTs), not RCT (12 studies),
different inclusion criteria (10 studies), lack of suit-
able translator (2 RCTs), data presentation inappropriateTable 7 Association between Sponsor and clinical outcomes:
Assessment
Growth Source of funding Positive*
n (%)$$
Weight gain N = 56 Industry 2 (3.6)
None/Not clear 2 (3.6)
Non industry 0
Length gain N = 40 Industry 3 (7.5)
None/Not clear
Non industry
Head Circumference N = 31 Industry 4 (12.9)
None /Not clear
Non industry
$$Overall percentage.
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically signif
groups (in favour of experimental group).
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically(1 RCT) and out of date [published before1980] (2 RCTs).
Three excluded RCTs were unpublished trials.
Characteristics of included studies
Table 1 lists included and on-going trials. Sixty seven
RCTs were included, 45 (67.2%) on full term infants, 22
(32.8%) on preterm infants. All included RCTs were
published trials. All trials were conducted on healthy fullGrowth
of outcome
Neutral* Chi-square p value Fisher’s exact p value
n (%)$$
35 (62.5) 0.309 0.266
10 (17.9)
7 (12.5)
29 (72.5) 0.667 1.00
6 (15)
2 (5)
23 (74.2) 0.712 1.00
3 (9.7)
1 (3.2)
icant effect, p < 0.05. There were significant differences between study
significant effect, p > 0.05, No significant differences between study groups.
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http://www.biomedcentral.com/1471-2288/13/137term or preterm infants and used standard (full term or
preterm) infant formula (Table 3).Funding
Out of 67 trials, 40 (59.7%) were funded by food indus-
try, 11 (16.4%) were funded by non-industry entities,
and 16 (23.9%) did not specify their source of funding,
10 RCTs on preterm infants, 6 RCTs on full infants
(Table 3).Methodological quality (Risk of bias)
In this review, several domains were not adequately re-
ported, particularly, the domains of sequence generation,
allocation concealment and blinding. Out of 67 RCTs,
25 (37.3%) failed to report sequence generation, 35
(52.2%) failed to report allocation concealment and 36
(53.7%) did not report blinding. Majority of the RCTs
were assessed as having a low risk of bias in the domains
of incomplete outcome data 52 (77.6%), selective reporting
57(85.1%) and other bias 53 (79.1%) (Table 4).Table 8 Association between Sponsor and clinical outcomes:
Tolerance Source of funding
Colic N = 13 Industry
None/Not clear
Non industry
Spitting up/Regurgitation N = 26 Industry
None/Not clear
Non industry
Vomiting N = 31 Industry
None/Not clear
Non industry
Crying fussiness N =22 Industry
None/Not clear
Non industry
Gastric residuals, Abdominal distension N = 5 Industry
None/Not clear
Non industry
Volume of formula consumed/daily intake N = 31 Industry
None/Not clear
Non industry
Days to full enteral feeding N = 9 Industry
None/Not clear
Non industry
$$Overall percentage.
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically signif
groups (in favour of experimental group).
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistic
study groups.
*Negative: synbiotic, probiotic or prebiotic supplementation had a statistically signOutcomes and study conclusions
In most RCTs, majority of outcomes were assessed as
neutral, (intervention did not have a statistically signifi-
cant effect, p > 0.05). A total of 49 (73.1%) of RCTs had a
positive overall study conclusion in favour of the spon-
sors’ products, while 7 (10.4%) had negative¸ 7 (10.4%)
had neutral conclusions and 4 (6%) had no clear conclu-
sion. The included RCTs either did not provide any con-
clusion on their reported clinical outcomes or, they
provided a positive conclusion for their reported out-
come in-favour of the sponsors’ products. Few RCTS
had either negative or neutral conclusions on their re-
ported clinical outcomes (Table 5).
Association between source of funding (sponsor) and
methodological quality of studies
There was no significant association between the source
of funding and the domains of sequence generation (Chi –
square p = 0.435, Fisher exact p = 0.465), allocation con-
cealment (Chi – square p = 0.315, Fisher exact p = 0.338),
blinding (Chi – square p = 0.395, Fisher exact p = 0.457)Tolerance symptoms
Positive* Negative* Neutral* Chi-square
p value
Fisher’s exact
p valuen (%)$$ n (%)$$ n (%)$$
1 (7.7) 11 (84.6) 0.764 1.00
1 (7.7)
2 (7.7) 1 (3.8) 17 (65.4) 0.907 1.00
4 (15.4)
2 (7.7)
1 (3.2) 23 (74.2) 0.860 1.00
5 (16.1)
2 (6.5)
3 (13.6) 1 (4.5) 14 (63.6) 0.581 1.00
4 (18.2)
0
1 (20) 0.659 1.00
1 (20)
1 (6.7) 2 (40)
3 (9.7) 1 (3.2) 18 (58.1) 0.758 1.00
4 (12.9)
5 (16.1)
4 (44.4) 0.325 0.444
1 (11.1) 1 (11.1)
1 (11.1) 2 (22.2)
icant effect, p < 0.05. There were significant differences between study
ally significant effect, p > 0.05, No significant differences between
ificant increase in an adverse event / negative outcome, p < 0.05.
Table 9 Association between sponsor and clinical outcomes: stool characteristics
Stool characteristics Source of funding Positive* Negative* Neutral* Chi-square
p value
Fisher’s exact
p valuen (%)$$ n (%)$$ n (%)$$
Stool Frequency N = 37 Industry 7 (18.9) 22 (59.5) 0.501 0.540
None/Not clear 3 (8.1) 4 (10.8)
Non industry 1 (2.7)
Stool Consistency n =37 Industry 14 (37.8) 15 (40.5) 0.562 1.00
None/Not clear 4 (10.8) 3 (8.1)
Non industry 1 (2.7)
Stool pH N =13 Industry 7 (53.8) 2 (15.4) 0.305 1.00
None/Not clear 4 (30.8)
Non industry
Stool Short Chain Fatty Acids N = 9 Industry 2 (22.2) 4 (44.4) 0.687 1.00
None / Not clear 1 (11.1) 1 (11.1)
Non industry 1 (11.1)
Flatulence / Gas N = 16 Industry 15 (93.8) Not valid
None/Not clear 1 (6.3)
Non industry 0
Diarrhoea, Diarrhoea episodes N = 19 Industry 3 (15.8) 1 (5.3) 10 (52.6) 0.771 1.00
None/Not clear 2 (10.5)
Non industry 3 (15.8)
Constipation N = 3 Industry 1 (33.3) 1 (33.3) 0.386 1.00
None/Not clear 1 (33.3)
Non industry 0
$$Overall percentage.
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study groups
(in favour of experimental group).
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups.
*Negative: synbiotic, probiotic or prebiotic supplementation had a statistically significant increase in an adverse event / negative outcome, p < 0.05.
Table 10 Association between sponsor and clinical outcomes: Microflora
Microflora Source of funding Positive 4* Negative 5* Neutral 6* Chi-square
p value
Fisher’s exact
p valuen (%)$$ n (%)$$ n (%)$$
Bifidobacteria N = 31 Industry 12 (38.7) 6 (19.4) 0.416 0.583
None/Not clear 8 (25.8) 2 (6.5)
Non industry 3 (9.7)
Lactobacillus N = 19 Industry 2 (10.5) 6 (31.6) 0.155 0.176
None/Not clear 4 (21.1) 5 (26.3)
Non industry 2 (10.5) 0
Pathogens N = 25 Industry 2 (8.0) 11 (44.0) 0.532 0.612
None/Not clear 3 (12.0) 1 (4.0) 6 (24.0)
Non industry 2 (8.0)
$$ Overall percentage.
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study
groups (in favour of experimental group).
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups.
*Negative: synbiotic, probiotic or prebiotic supplementation had a statistically significant increase in an adverse event / negative outcome, p < 0.05.
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Table 11 Association between sponsor and clinical outcomes: Necrotizing enterocolitis, sepsis and antibiotic use
Source of funding Positive* Neutral* Chi-square
p value
Fisher’s exact
p valuen (%)$$ n (%)$$
Necrotising enterocolitis N = 11 Industry 4 (36.4) 0.118 0.273
None/Not clear 3 (27.3)
Non industry 2 (18.2) 2 (18.2)
Sepsis N = 10 Industry 2 (20) Not Valid
None/Not clear 3 (30)
Non industry 5 (50)
Antibiotic use N = 19 Industry 4 (21.1) 4 (21.1) 0.031# 0.039#
None/Not clear 5 (26.3)
Non industry 6 (31.6)
$$ Overall percentage.
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study
groups (in favour of experimental group).
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups.
# Significant p < 0.05.
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http://www.biomedcentral.com/1471-2288/13/137and selective reporting (Chi – square p = 0.224, Fisher
exact p = 0.188) (Table 6).
There was a significant association between funding
and the domains of incomplete outcome data (Chi –
square p = 0.023, Fisher exact p = 0.005) and free of
other bias (Chi – square p = 0.033, Fisher exact p =
0.038) (Table 6). The association between source of
funding and incomplete outcome data was such that
industry-funded trials had significantly less missing data
than non-industry funded trials. The association between
source of funding and free of other bias (such as out-
comes bias) was such that a significantly higher percent-
age of industry-funded trials were free of other bias
compared to non-industry-funded trials.
Association between source of funding (sponsor) and
clinical outcomes
There was no significant association between source of
funding and reporting of clinical outcomes: Growth pa-
rameters, stool characteristics, microflora, infections
(Tables 7, 8, 9, 10 and 11), immune parameters, adverse
events and mortality (data not shown). There was a
significant association between the source of funding
and reporting of antibiotic use in formula fed infants
(Chi-square p = 0.031, Fisher exact p = 0.039) such thatTable 12 Association between sponsor and OVERALL study co
Source of funding Positive Negative Ne
n (%)$$ n (%)$$ n
Overall conclusion N = 67 Industry 32 (47.8) 2 (3.0) 3
None/Not clear 10 (14.9) 3 (4.5) 2
Non industry 7 (10.4) 2 (3.0) 2
Total 49 (73.1%) 7 (10.4%) 7 (
$$ Overall percentage.industry funded trials were more likely to decrease the
use of antibiotics than non-industry funded trials
(Table 11).
Association between source of funding (sponsor) and
overall study conclusion
There was no significant association between sources of
funding and overall study conclusion (Chi-square p =
0.505, Fisher exact p = 0.373). Majority of RCTs, 49
(73.1%), had a positive study conclusion; 32 (47.8%) of
these RCTs, were industry sponsored, 7 (10.4%) non- in-
dustry and 10 (14.9%) which did not declare their source
of funding (Table 12). A sensitivity analysis was con-
ducted with respect to combining industry sponsored
studies with those that had not declared their source of
funding. There was no change in the results. There was
no significant association between source of funding and
overall study conclusion (Chi-square p = 0.483, Fisher
exact p = 0.425).
Association between source of funding (sponsor) and
conclusion on reported clinical outcomes
There was a significant association between source of
funding and conclusion on weight gain (Chi-square p =
0.037, Fisher exact p = 0.024) such that industry-fundednclusion
utral No clear conclusion Total Chi-square
p value
Fisher’s exact
p value(%)$$ n (%)$$ n (%)$$
(4.5) 3 (4.5) 40 (59.7%) 0.505 0.373
(3.0) 1 (1.5) 16 (23.9%)
(3.0) 0 11 (16.4%)
10.4%) 4 (6.0%) 67 (100)
Table 13 Association between sponsor and conclusion on reported outcome: Growth parameters
Authors conclusion on: Source of funding No conclusion on reported outcome Positive Negative Chi-square
p value
Fisher’s exact
p valuen (%)$$ n (%)$$ n (%)$$
Weight gain N = 56 Industry 23 (41.1%) 14 (25.0%) 0.037# 0.024#
None/Not clear 10 (17.9%) 1 (1.8%) 1 (1.8%)
Non industry 7 (12.5%)
Length gain N = 40 Industry 18 (45%) 14 (35%) 0.068 0.051
None/Not clear 6 (15%)
Non industry 2 (5)
Head circumference N = 31 Industry 13 (41.9) 14 (45.2) 0.151 0.232
None/Not clear 3 (9.7)
Non industry 1 (3.2)
#Significant p < 0.05, $$ Overall percentage.
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http://www.biomedcentral.com/1471-2288/13/137trials were more likely to report positive conclusions on
weight gain than non-industry-funded trials (Table 13).
There was no significant association between source of
funding and conclusion on other reported clinical out-
comes (Tables 14, 15, 16 and 17).Table 14 Association between sponsor and conclusion on rep
Tolerance Source of funding No conclusion on
n
Colic N = 13 Industry 10 (76.9)
None/Not clear
Non industry 1 (7.7)
Spitting up/Regurgitation N = 26 Industry 19 (73.1)
None/Not clear 2 (7.7)
Non industry 2 (7.7)
Vomiting N = 32 Industry 19 (59.4)
None/Not clear 3 (9.4)
Non industry 2 (6.3)
Crying Fussiness N =20 Industry 10 (50)
None/Not clear 2 (10)
Non industry 0
Gastric residuals, Abdominal
distension N = 6
Industry
None/Not clear 1 (16.7)
Non industry 2 (33.3)
Volume of formula consumed/daily
intake N = 30
Industry 19 (63.3)
None/Not clear 3 (10.0)
Non industry 4 (13.3)
Days to full enteral feeding N = 8 Industry 2 (25)
None/Not clear 1 (12.5)
Non industry 2 ()25
$$Overall percentage.Discussion
This review revealed that majority of RCTs (from 1980
to 2012) on infants fed formula supplemented with pro-
biotics, prebiotics or synbiotics are funded by the food
industry. This is consistent with the trend thatorted outcome: Tolerance symptoms
reported outcome Positive Negative Chi-square
p value
Fisher’s exact
p value(%)$$ n (%)$$ n (%)$$
2 (15.4) 0.657 1.00
1 (3.8) 0.032 0.062
2 (7.7)
5 (15.6)
3 (9.4)
6 (30) 0.648 1.00
2 (10)
1 (16.7) 0.513 1.00
1 (16.7)
1 (16.7)
2 (6.7) 1 (3.3) 0.867 0.733
1 (3.3)
1 (12.5) 0.547 1.00
1 (12.5)
1 (12.5)
Table 15 Association between sponsor and conclusion on reported outcome: Stool characteristics
Stool characteristics Source of funding No conclusion on reported outcome
n (%)$$
Positive Negative Pearson’s
chi Square
Fisher’s exact
p valuen (%)$$ n (%)$$
Stool frequency N = 38 Industry 21 (55.3) 9 (23.7) 0.809 1.00
None / Not clear 5 (13.2) 2 (5.3)
Non industry 1 (2.6)
Total 27 (71.1) 11 (28.9)
Stool consistency n =39 Industry 18 (46.2) 13 (33.3) 0.699 1.00
None / Not clear 4 (10.3) 3 (7.7)
Non industry 1 (2.6)
Total 23 (59) 16 (41)
Stool pH N =12 Industry 5 (41.7) 3 (25) 0.679 1.00
None / Not clear 2 (16.7) 2 (16.7)
Non industry
Total 7 (58.3) 5 (41.7)
Stool short chain fatty acids N = 9 Industry 3 (33.3) 3 (33.3) 0.638 1.00
None / Not clear 1 (11.1) 1 (11.1)
Non industry 1 (11.1)
Total 5 (55.6) 4 (44.4)
Flatulence/Gas N = 15 Industry 10 (66.7) 4 (26.7) 0.533 1.00
None / Not clear
Non industry 1 (6.7)
Total 11 (73.3) 4 (26.7)
Diarrhoea, Diarrhoea episodes N = 18 Industry 7 (38.9) 5 (27.8) 1 (5.6) 0.484 0.557
None / Not clear 2 (11.1)
Non industry 3 (16.7)
Total 12 (66.7) 5 (27.8) 1 (5.6)
Constipation N = 4 Industry 2 (50) 1 (25) 0.505 1.00
None / Not clear
Non industry 1(25)
Total 3 (75) 1 (25) 1 (25)
$$ Overall percentage.
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http://www.biomedcentral.com/1471-2288/13/137biomedical research is increasingly being funded by in-
dustry [1,2] There was a trend that more RCTs on pre-
term infants failed to report their source of funding. The
reason(s) for this trend needs to be explored further.
Cochrane guidelines were used to assess the risk of bias
of included RCTs. The reporting of several domains was
however suboptimal particularly sequence generation,
allocation concealment and blinding domains. Considering
completed data, there was no significant association be-
tween funding source and methodological quality of RCTs
in the domains of sequence generation, allocation conceal-
ment, blinding and selective reporting. There was a signifi-
cant association between funding and methodological
quality of RCTs in the domains of incomplete outcome
data and free of other bias. Industry funded trials had sig-
nificantly less missing data than non-industry funded trials.
A higher percentage of industry funded trials were freeof other bias compared to non-industry funded trials. More
industry sponsored trials had low risk of bias in 5 out of 6
domains, even though our results did not show a statistical
significant association between funding and methodo-
logical quality in most domains. Our results confirm find-
ings from previous reviews on infants given enteral feeds
with probiotics, prebiotics and synbiotics [157-159].
There was no significant association between funding
source and clinical outcomes or majority of authors’
conclusions. There was a significant association between
funding and conclusion on weight gain. Regardless of
the reported clinical outcomes, nearly all RCTs in this
review reported neutral results. That is supplementation
with probiotics, prebiotics or synbiotics did not have a
significant effect or there were no significant differences
between study groups of infants given supplemented for-
mula or placebo. Our findings confirm the results of two
Table 16 Association between sponsor and conclusion on reported outcome: Microflora
Microflora Source of funding No conclusion on reported outcome Positive Negative Neutral Chi-square
p value
Fisher’s exact
p valuen (%)$$ n (%)$$ n (%)$$ n (%)$$
Bifidobacteria N = 30 Industry 7 (23.3) 11 (36.7) 0.249 0.195
None/Not clear 2 (6.7) 5 (16.7) 1 (3.3) 1 (3.3)
Non industry 1 (3.3) 1 (3.3) 1 (3.3)
Lactobacillus N = 19 Industry 5 (26.3) 4 (21.1) 0.084 0.294
None/Not clear 3 (15.8) 4 (21.1) 1 (5.3)
Non industry 1 (5.3) 1 (5.3)
Pathogens N = 25 Industry 7 (28) 6 (24) 0.152 0.269
None/Not clear 4 (16) 5 (20) 1 (4)
Non industry 1 (4) 1 (4)
$$Overall percentage.
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http://www.biomedcentral.com/1471-2288/13/137systematic reviews which found that supplementation
with probiotics, prebiotics or synbiotics did not offer any
distinct advantage over placebo [158,159]. However, re-
sults of this review did not agree with two nutrition re-
lated reviews or reviews on pharmaceutical industry
supported RCTs, which reported that industry sponsored
RCTs had results and conclusions in favour of the spon-
sor [2-4,6,8,160-162]. Despite reporting neutral out-
comes, authors from industry sponsored RCTs had a
tendency to advocate for the consumption of the sponsors’
products. Similar findings were reported by Nestle, who re-
ported that research investigators “who received company
grants tended to publish results, give advice and prescribe
in favour of the sponsor.” This applied to research that was
supported by pharmaceutical and food industries [163].
Effects of sponsorship on overall study conclusion
have been equally documented in biomedical literature.
Reviews by Lessor and Nkansah reported positive con-
clusions in favour of the sponsor [6,8]. Although no sta-
tistically significant association between funding andTable 17 Association between sponsor and conclusion on rep
antibiotic use
Source of funding No conclusion on reporte
n (%)$$
NEC N = 12 Industry 3 (25)
None/Not clear 2 (16.7)
Non industry 2 (16.7)
7 (58.3)
Sepsis N = 10 Industry 2 (20)
None/Not clear 2 (20)
Non industry 5 (50)
Antibiotic use N = 16 Industry 4 (25)
None/Not clear 4 (25)
Non industry 5 (31.3)
$$ Overall percentage.authors conclusion was found in this review, more than
70% of RCTs reported positive conclusions, 47.8% of
these were industry sponsored. Often, these positive
conclusions in the RCTs were not supported by the re-
ported data as demonstrated by the neutral clinical out-
comes. Our findings are consistent with those of previous
reviews, which found that, results from RCTs may be ac-
curate, but authors may distort the meaning of the results,
present conclusions that are more favourable, and that
were not supported by the data presented [2,5,163]. Even
meta – analyses were not spared from this trend [2,5,163].
Despite overwhelming positive overall study conclusions,
majority of RCTs did not have any conclusion on their re-
ported clinical outcomes. The RCTs that reported any
conclusion on their clinical outcomes, majority were posi-
tive in favour of the sponsors’ products.
Limitations
This review did not document the role of the sponsor in
study design, data collection, and analysis. Few RCTsorted outcome: Necrotising Enterocolitis Sepsis and
d outcome Positive Negative Pearson’s
chi Square
Fisher’s exact
p valuen (%)$$ n (%)$$
1 (8.3) 0.511 0.782
1 (8.3) 1 (8.3)
2 (16.7) 0
3 (25) 2 (16.7)
0.274 0.500
1 (10)
3 (18.8) 0.093 0.141
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http://www.biomedcentral.com/1471-2288/13/137reported this. More detailed documentation and disclos-
ure in RCT reports would help evaluate if there was an
association between funding and reported outcomes or
conclusions. Many RCTs had missing data especially on
the domains of sequence generation, allocation conceal-
ment and blinding. Attempts were made to contact
authors for missing information but none responded.
The sample size (number of RCTs) was small and
skewed towards industry.Conclusion
This study assessed the impact of funding by the food
industry on trial outcomes and methodological quality
of synbiotics, probiotics and prebiotics research in in-
fants. There was no significant association between
source of funding and methodological quality of study in
the domains of sequence generation, allocation conceal-
ment and blinding. Industry funded trials had less miss-
ing data and were free of other bias than non-industry
funded trials.
There was no significant association between funding
and majority of reported clinical outcomes or authors’
conclusions. However, there was a significant association
between funding source and reported antibiotic use and
conclusion on weight gain. Majority of RCTs were in-
dustry funded, more non-industry funded research is
needed to further assess the impact of funding on meth-
odological quality, reported clinical outcomes and au-
thors’ conclusions.
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